Investigating anxiolytic effect of intranasal micro emulsion in experimental animal models
DOI:
https://doi.org/10.56511/JIPBS.2024.11103Abstract
This investigation aimed to assess the anxiolytic potential of an intranasal micro emulsion formulation in an experimental model utilizing Swiss Albino Mice. The evaluation of anti-anxiety activity was conducted through the Elevated plus Maze and Open Field tests. In the Elevated plus Maze, parameters such as the total count of arm entries and the duration spent in both open and enclosed arms were meticulously recorded. Similarly, the Open Field tests involved the documentation of entries in the central region, the time spent in the central region, entries into the peripheral zone, and time spent in the peripheral zone. The experimental subjects received treatment with the intranasal micro emulsion formulation at a dosage of 50mg/kg. The results from the Elevated plus Maze exhibited a noteworthy (p<0.01**) augmentation in the quantity of entries and the duration of sojourn within the open arm. Parallelly, the Open Field tests revealed a significant (p<0.01**) escalation in the count of squares traversed and the frequency of crossings. This investigation unequivocally indicated that the intranasal micro emulsion formulation elicited a pronounced anti-anxiety effect in the experimental animal model. This research contributes to the expanding body of knowledge on the potential therapeutic efficacy of intranasal micro emulsion formulations in addressing anxiety-related behaviors, thereby paving the way for further investigations and potential clinical applications
Keywords:
Anti-anxiety, Intranasal micro emulsion, Elevated plus maze, Open field test.Downloads
References
World Health Organization (WHO). (2017). Depression and Other Common Mental Disorders: 2017; Global Health Estimates.
Anxiety and Depression Association of America (ADAA). (n.d.). Facts & Statistics.
Somers, J. M., Goldner, E. M., Waraich, P., & Hsu, L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Canadian Journal of Psychiatry . 2006; 51(2) : 100 - 113.
Shri R . Anxiety: causes and management. J Behav Sci . 2010 ; 5:100 – 118.
Kessler RC, Greenberg PE: The economic burden of anxiety and stress disorders. In Neuropsychopharmacology: the fifth generation of progress: American College of Neuropsychopharmacology. Edited by Kenneth LD, Dennis C, Joseph TC, Charles N. Philadelphia, Lippincott: Williams & Wilkins; 2002.
Hoffman DL, Dukes EM, Wittchen HU . Human and economic burden of generalized anxiety disorder. Depress Anxiety . 2008 ; 25(1):72 – 90.
Eysenck MW, Derakshan N . New perspectives in attentional control theory. Personal Individ Differ 2011 ; 509:55 – 960.
Durant C, Christmas D, Nutt D . The pharmacology of anxiety. Curr Top Behav Neurosci . 2010 ; 2:303 – 330.
Marohn S: What is Anxiety and Who Suffers from it? The Natural Medicine Guide to Anxiety. Newburyport, Massachusetts: Hampton Roads Publishing Company; 2003.
Atack JR: GABAA receptor α 2/ α 3 subtype - selective modulators as potential nonsedating anxiolytics. Curr Top Behav Neurosci . 2010 ; 2:331 – 360.
Treit D, Engin E, McEown K . Animal models of anxiety and anxiolytic drug action. Curr Top Behav Neurosci . 2010 ; 2:21 – 60.
Nastassja K, Dan JS . Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci . 2011 ; 13(4):423 – 437.
Hood S, Ayonrinde D, Davidson R, Martin - Iverson M, Samuel M, Schenk M, Sim M, Wynn Owen P, Lyon D: Anxiety Disorders Drug Treatment Guidelines. Perth, WA, Australia: Western Australian Psychotropic Drugs Committee, Western Australian Therapeutics Advisory Group; 2008.
Ravindran LN, Stein MB: Pharmacotherapy of post - traumatic stress disorder. Curr Top Behav Neurosci . 2010 ; 2:505 – 525.
Yorbik Ö, Birmaher B: Pharmacological treatment of anxiety disorders in children and adolescents. Bull Clin Psychopharmacol . 2003 ; 13:133 – 141.
Gray J: Therapeutic choices. 4th edition. Ottawa, Canada: Canadian Pharmacist Association; 2003.
Mahe V, Balogh A: Long - term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol 2000 ; 15:99 – 105.
Zhang ZJ: Therapeutic effects of herbal extracts and constituents in animal models of psychiatric disorders. Life Sci . 2004 ; 75:1659 – 1699
Zarei MH, Lorigooini Z, Khoei HA, Bijad E. Acute oral toxicity assessment of galbanic acid in albino rat according to OECD 425 TG. Toxicology Reports. 2023; 11:111 - 5.
Kulkarni SK. Practical Pharmacology and Clinical Pharmacy. 1st ed. Delhi: Vallabh Prakasan;2009.
Alshahrani AM . In vivo neurological assessment of sedative hypnotic effect of Coriandrum Sativum L. seeds in mice. Int J Phytomed 2016; 8(1):113 - 6.
Rauniar GP, Deo S, Bhattacharya SK . Evaluation of anxiolytic activity of tensarin in mice. Kathmandu Univ Med J 2007; 18:188 – 194.
Rajput MA, Khan RA, Feroz Z . Evaluation of anxiolytic activity of methanol extract of Trachyspermum Ammi. L. Int J Pharm Pharm Sci . 2015; 7:69 – 71.
Riaz A, Khan RA Effect of Punica granatum on behavior in rats. Afr J Pharm Pharmacol 2014; 8:1118 – 1126.
Dawson GR, Tricklebank MD. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences. 1995; 16(2):33 - 6. https://doi.org/10.1016/S0165 - 6147(00)88973 - 7
Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus - maze as a measure of anxiety in the rat. Journal of Neuroscience Methods. 1985;14(3):149 - 67. https://doi.org/10.1016/01650270(85)90031 - 7.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Ansari Vikhar Danish Ahmad, Subur W Khan
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Innovations in Pharmaceutical and Biological Sciences is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Based on a work at